A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

NCT04122976 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

805

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Darolutamide(Nubeqa, BAY1841788)

Sponsor

Bayer